#32: Pharmacogenomics and Companion Diagnostics: The Future of Clinical Trials, New Product Development and the Practice of Medicine Day & Time:
June 15, 1:00PM - 4:30PM (Pacific Standard Time)Room Number:
Michael Drues, PhD
Founder and President
Vascular Sciences, United StatesDescription:Maximize your learning while attending the DIA 2014 50th Annual Meeting! Receive $100 off of your DIA 2014 meeting registration by registering for two half-day tutorials or one full-day tutorial. Purchases must be made at the same time in order to receive the discount.
It is often not enough for pharmaceutical companies simply to bring a drug to market. Regulators and insurers are also encouraging companies to develop pharmacogenomic tools such as companion diagnostics to pinpoint which patients are most likely to benefit from a drug, thereby sparing other patients from needless side effects and expense. Pharmacogenomics represents a growing component of medical technology. This tutorial will discuss the way clinical trials are designed and conducted, how it will revolutionize new product development, and how it will change the way we practice medicine. This technology can do so much more: pharmacogenomic technology is quickly evolving and the future will look much different than it does today. During this interactive tutorial, participants will be exposed to multiple examples of pharmacogenomic applications currently on the market, under development, and on the drawing board.
|#32: Pharmacogenomics and Companion Diagnostics||ACPE|
At the conclusion of this tutorial, participants should be able to:
• Identify how pharmacogenomic and companion diagnostic technologies are used today;
• Discuss current regulatory requirements and how to implement them;
• Identify how regulation will change as these emerging technologies evolve;
• Describe how pharmacogenomics and companion diagnostics are impacting clinical trial design, new product development, and the practice of medicine.
This tutorial is designed for professionals involved with combination products, companion diagnostics, personalized medicine, and pharmacogenomics.